Induction of two distinct natural killer-cell populations, activated T cells and antineoplastic cytokines, by interleukin-2 therapy in children with solid tumors

D. Dilloo, H. J. Laws, H. Hanenberg, D. Korholz, W. Nurnberger, S. E G Burdach

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Children with poor prognoses regarding solid tumors have benefited from autologous bone marrow transplantation as a treatment modality. Posttransplantation adjuvant interleukin-2 (IL-2) therapy has previously been shown to improve prognosis in adults with neoplastic disease. The improved survival probability has been attributed to IL-2-mediated stimulation of the immune system and its antineoplastic activity. In this study, 10 pediatric patients with solid tumors in complete remission after autologous stem cell transplantation were treated with recombinant IL-2, which was administered in three 5-day cycles of continuous intravenous infusions with a 2-week rest in between cycles. We demonstrated that IL-2 therapy enhanced transplantation-related stimulation of the immune system, on both the cellular and humoral levels. Peripheral blood T and natural killer (NK) cells increased by the factors four and 14, respectively. Activation of the immune system was demonstrated by significantly elevated levels of soluble IL-2 receptor (IL-2R) and increased CD25 surface expression on T lymphocytes. IL-2 also induced significant proliferation of the CD56(bright) NK-cell subpopulation that appears post-bone marrow transplant (BMT) and is found only in minimal amounts in normal controls. In vivo and in vitro production of tumor cytotoxic cytokines tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) was significantly stimulated following IL-2 therapy, further indicating IL-2-mediated stimulation of the antineoplastic activity of the immune system.

Original languageEnglish (US)
Pages (from-to)1081-1088
Number of pages8
JournalExperimental Hematology
Volume22
Issue number11
StatePublished - 1994
Externally publishedYes

Fingerprint

Natural Killer Cells
Antineoplastic Agents
Interleukin-2
Cytokines
T-Lymphocytes
Immune System
Population
Neoplasms
Therapeutics
Natural Killer T-Cells
Autologous Transplantation
Interleukin-2 Receptors
Stem Cell Transplantation
Bone Marrow Transplantation
Intravenous Infusions
Interferons
Tumor Necrosis Factor-alpha
Transplantation
Bone Marrow
Pediatrics

Keywords

  • BMT
  • Cytokines
  • IL-2 therapy
  • NK-cell subpopulations

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Genetics
  • Hematology
  • Oncology
  • Transplantation

Cite this

Induction of two distinct natural killer-cell populations, activated T cells and antineoplastic cytokines, by interleukin-2 therapy in children with solid tumors. / Dilloo, D.; Laws, H. J.; Hanenberg, H.; Korholz, D.; Nurnberger, W.; Burdach, S. E G.

In: Experimental Hematology, Vol. 22, No. 11, 1994, p. 1081-1088.

Research output: Contribution to journalArticle

Dilloo, D. ; Laws, H. J. ; Hanenberg, H. ; Korholz, D. ; Nurnberger, W. ; Burdach, S. E G. / Induction of two distinct natural killer-cell populations, activated T cells and antineoplastic cytokines, by interleukin-2 therapy in children with solid tumors. In: Experimental Hematology. 1994 ; Vol. 22, No. 11. pp. 1081-1088.
@article{b0f5cdbaae2f4bbb90cf4956ad86165a,
title = "Induction of two distinct natural killer-cell populations, activated T cells and antineoplastic cytokines, by interleukin-2 therapy in children with solid tumors",
abstract = "Children with poor prognoses regarding solid tumors have benefited from autologous bone marrow transplantation as a treatment modality. Posttransplantation adjuvant interleukin-2 (IL-2) therapy has previously been shown to improve prognosis in adults with neoplastic disease. The improved survival probability has been attributed to IL-2-mediated stimulation of the immune system and its antineoplastic activity. In this study, 10 pediatric patients with solid tumors in complete remission after autologous stem cell transplantation were treated with recombinant IL-2, which was administered in three 5-day cycles of continuous intravenous infusions with a 2-week rest in between cycles. We demonstrated that IL-2 therapy enhanced transplantation-related stimulation of the immune system, on both the cellular and humoral levels. Peripheral blood T and natural killer (NK) cells increased by the factors four and 14, respectively. Activation of the immune system was demonstrated by significantly elevated levels of soluble IL-2 receptor (IL-2R) and increased CD25 surface expression on T lymphocytes. IL-2 also induced significant proliferation of the CD56(bright) NK-cell subpopulation that appears post-bone marrow transplant (BMT) and is found only in minimal amounts in normal controls. In vivo and in vitro production of tumor cytotoxic cytokines tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) was significantly stimulated following IL-2 therapy, further indicating IL-2-mediated stimulation of the antineoplastic activity of the immune system.",
keywords = "BMT, Cytokines, IL-2 therapy, NK-cell subpopulations",
author = "D. Dilloo and Laws, {H. J.} and H. Hanenberg and D. Korholz and W. Nurnberger and Burdach, {S. E G}",
year = "1994",
language = "English (US)",
volume = "22",
pages = "1081--1088",
journal = "Experimental Hematology",
issn = "0301-472X",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Induction of two distinct natural killer-cell populations, activated T cells and antineoplastic cytokines, by interleukin-2 therapy in children with solid tumors

AU - Dilloo, D.

AU - Laws, H. J.

AU - Hanenberg, H.

AU - Korholz, D.

AU - Nurnberger, W.

AU - Burdach, S. E G

PY - 1994

Y1 - 1994

N2 - Children with poor prognoses regarding solid tumors have benefited from autologous bone marrow transplantation as a treatment modality. Posttransplantation adjuvant interleukin-2 (IL-2) therapy has previously been shown to improve prognosis in adults with neoplastic disease. The improved survival probability has been attributed to IL-2-mediated stimulation of the immune system and its antineoplastic activity. In this study, 10 pediatric patients with solid tumors in complete remission after autologous stem cell transplantation were treated with recombinant IL-2, which was administered in three 5-day cycles of continuous intravenous infusions with a 2-week rest in between cycles. We demonstrated that IL-2 therapy enhanced transplantation-related stimulation of the immune system, on both the cellular and humoral levels. Peripheral blood T and natural killer (NK) cells increased by the factors four and 14, respectively. Activation of the immune system was demonstrated by significantly elevated levels of soluble IL-2 receptor (IL-2R) and increased CD25 surface expression on T lymphocytes. IL-2 also induced significant proliferation of the CD56(bright) NK-cell subpopulation that appears post-bone marrow transplant (BMT) and is found only in minimal amounts in normal controls. In vivo and in vitro production of tumor cytotoxic cytokines tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) was significantly stimulated following IL-2 therapy, further indicating IL-2-mediated stimulation of the antineoplastic activity of the immune system.

AB - Children with poor prognoses regarding solid tumors have benefited from autologous bone marrow transplantation as a treatment modality. Posttransplantation adjuvant interleukin-2 (IL-2) therapy has previously been shown to improve prognosis in adults with neoplastic disease. The improved survival probability has been attributed to IL-2-mediated stimulation of the immune system and its antineoplastic activity. In this study, 10 pediatric patients with solid tumors in complete remission after autologous stem cell transplantation were treated with recombinant IL-2, which was administered in three 5-day cycles of continuous intravenous infusions with a 2-week rest in between cycles. We demonstrated that IL-2 therapy enhanced transplantation-related stimulation of the immune system, on both the cellular and humoral levels. Peripheral blood T and natural killer (NK) cells increased by the factors four and 14, respectively. Activation of the immune system was demonstrated by significantly elevated levels of soluble IL-2 receptor (IL-2R) and increased CD25 surface expression on T lymphocytes. IL-2 also induced significant proliferation of the CD56(bright) NK-cell subpopulation that appears post-bone marrow transplant (BMT) and is found only in minimal amounts in normal controls. In vivo and in vitro production of tumor cytotoxic cytokines tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) was significantly stimulated following IL-2 therapy, further indicating IL-2-mediated stimulation of the antineoplastic activity of the immune system.

KW - BMT

KW - Cytokines

KW - IL-2 therapy

KW - NK-cell subpopulations

UR - http://www.scopus.com/inward/record.url?scp=0028113113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028113113&partnerID=8YFLogxK

M3 - Article

C2 - 7925775

AN - SCOPUS:0028113113

VL - 22

SP - 1081

EP - 1088

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

IS - 11

ER -